Assay Design Technology Licensed from
Fusions genes are hybrid genes formed from two previously separate genes. An increasing number of these genes are being recognized as important diagnostic and prognostic indicators in human cancers and diseases. nCounter Elements GPRs enable clinical laboratories to independently develop multiplexed genomic assays and then rapidly translate those assays into clinical diagnostics as Laboratory Developed Tests (LDTs).
NanoString's new junction probe design was created based on technology
developed by Peng Yin Ph.D., core faculty member at the
Comprehensive fusion assays, based on these design methods, can accurately detect fusion events in formalin-fixed, paraffin embedded (FFPE) and fresh frozen patient tissue as well as cell lines. Flexibility in design options and multiplexing capabilities enable development of assays for a variety of applications from discovery to diagnostics.
"These multiplexed fusion assays offer an alternative to singleplex
FISH, qPCR, and IHC assays that maximizes the information generated from
scarce samples and enables the addition of new fusions without an
increase in sample input amount or labor," said Dr.
This offering expands on NanoString's established strength in fusion
gene analysis as previously published in "A Single-Tube Multiplexed
Assay for Detecting ALK, ROS1, and RET Fusions in
The nCounter Elements reagents are available for use in developing LDTs,
pursuant to a licensing arrangement offered by
For more information, please visit www.NanoString.com.
News Provided by Acquire Media